Your browser doesn't support javascript.
loading
Midazolam Indications and Dosing in Palliative Medicine: Results from a Multinational Survey.
Tranung, Morten; Solheim, Tora Skeidsvoll; Løhre, Erik Torbjørn; Marsaa, Kristoffer; Faksvåg Haugen, Dagny; Laird, Barry; Thronæs, Morten; Due Larsen, Michael.
Afiliação
  • Tranung M; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.
  • Solheim TS; Department of Clinical Pharmacy, Trondheim Hospital Pharmacy, 7030 Trondheim, Norway.
  • Løhre ET; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.
  • Marsaa K; Cancer Clinic, Trondheim University Hospital, St. Olavs Hospital, 7030 Trondheim, Norway.
  • Faksvåg Haugen D; Department of Clinical and Molecular Medicine, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, 7034 Trondheim, Norway.
  • Laird B; Cancer Clinic, Trondheim University Hospital, St. Olavs Hospital, 7030 Trondheim, Norway.
  • Thronæs M; Centre for Crisis Psychology, Faculty of Psychology, University of Bergen, 5006 Bergen, Norway.
  • Due Larsen M; Department of Multidisease, Copenhagen University Hospital-North Zealand, 3400 Hilleroed, Denmark.
Curr Oncol ; 31(7): 4093-4104, 2024 Jul 19.
Article em En | MEDLINE | ID: mdl-39057177
ABSTRACT
Despite sparse evidence and limited guidance on indications, use, and dosing, midazolam is widely used in palliative care. We aimed to describe and compare the use of midazolam in three different countries to improve clinical practice in palliative care. We performed an online survey among palliative care physicians in Norway, Denmark, and the United Kingdom (UK). The focus was indications, dosing, administration, and concomitant drugs. A web-based questionnaire was distributed to members of the respective national palliative medicine associations. The total response rate was 9.4%. Practices in the UK, Norway, and Denmark were overall similar regarding the indications of midazolam for anxiety, dyspnoea, and pain treatment in combination with opioids. However, physicians in the UK used a higher starting dose for anxiety, dyspnoea, and pain treatment compared to Norway and Denmark, as well as a higher maximum dose. Danish physicians preferred, to a higher degree, on-demand midazolam administration. Despite practice similarities in the UK, Norway, and Denmark, differences exist for midazolam dosing and administration in palliative medicine. We demonstrated a lack of consensus on how midazolam should be used in palliative care, setting the stage for future studies on the topic.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cuidados Paliativos / Midazolam Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Curr Oncol Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Cuidados Paliativos / Midazolam Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Curr Oncol Ano de publicação: 2024 Tipo de documento: Article